drugset / Trial / NCT00107796

Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy

NCT00107796

Phase 3 Completed 140 enrolled Cephalon
RandomizedParallel-groupDouble-blindTreatment

Summary

Primary Objectives: The primary objectives of the study are to determine the effectiveness of PROVIGIL treatment, compared to placebo treatment, in children and adolescents with excessive sleepiness (ES) associated with narcolepsy, as assessed by: * mean sleep latency from the Multiple Sleep Latency Test (MSLT) (average of 4 naps performed at 0900, 1100, 1300, and 1500) at the last post-baseline observation (week 6 or early termination) * the Clinical Global Impression of Change (CGI-C) ratings for ES, at the last post-baseline observation (week 6 or early termination).

Timeline

Start
2004-10
Primary completion
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Modafinil Small molecule 100 mg
Subject Modafinil Small molecule 200 mg
Subject Modafinil Small molecule 400 mg

Indications